Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Upadacitinib is a selective JAK-1 inhibitor approved for the treatment of rheumatoid arthritis and more recently, ulcerative colitis. Phase II trials demonstrated that upadacitinib induces endoscopic remission in patients with moderate-to-severe Crohn's disease. However, real-world data are lacking. We present a short report on our experience with off-label upadacitinib in patients with CD at a tertiary center. In this cohort of medically refractory patients with CD, treatment with upadacitinib resulted in subjective and objective responses in 25 and 42% of patients, respectively. Even at doses that are considered lower than currently being studied for CD, upadacitinib was associated with a favorable benefit-to-risk profile.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s10620-022-07582-w | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Prevalence and risk factors of metabolic dysfunction-associated steatotic liver disease in patients with inflammatory bowel disease.
Eur J Gastroenterol Hepatol
September 2025
Division of Gastroenterology and Hepatology, Department of Internal Medicine, School of Medicine, The University of Jordan, Jordan University Hospital.
Aim: The purpose of our study was to evaluate the prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD) and its associated risk factors in patients with inflammatory bowel disease (IBD).
Methods: This was a retrospective chart review of patients who underwent treatment for IBD at Jordan University Hospital between January 2013 and 2022. Case finding methods and clinical chart reviews were used to evaluate the clinical profile of patients with IBD.
Exploring the molecular mechanism of Crohn's disease and rheumatoid arthritis: a bioinformatics and functional analysis approach.
Eur J Gastroenterol Hepatol
September 2025
Department of Gastroenterology, First Affiliated Hospital of Shantou University Medical College, Shantou.
Background: Crohn's disease (CD) and rheumatoid arthritis (RA) are autoimmune diseases. CD is known to be closely associated with RA. However, the mechanisms underlying these relationships remain unclear.
View Article and Find Full Text PDFFeasibility and Preliminary Efficacy of combined home-based fecal calprotectin self-testing and therapeutic drug monitoring-guided intervention in Patients with moderate-to-severe inflammatory bowel disease.
Eur J Gastroenterol Hepatol
August 2025
Department of Gastroenterology, The Affiliated Wuxi People's Hospital of Nanjing Medical University, Wuxi Medical Center, Nanjing Medical University, Wuxi People's Hospital, Wuxi, Jiangsu Province, China.
Background: Inflammatory bowel diseases (IBD), including Crohn's disease and ulcerative colitis, significantly impact patients' lives. Effective management often involves invasive and costly monitoring.
Objective: To evaluate the feasibility of integrating home-based fecal calprotectin testing with therapeutic drug monitoring (TDM) in managing moderate-to-severe IBD.
Evaluating the completeness of postoperative endoscopic recurrence assessment in Crohn's disease patients with Kono-S anastomoses.
Eur J Gastroenterol Hepatol
August 2025
Department of Gastroenterology and Hepatology, Monash Health.
Background And Aims: Despite therapeutic advances, resection rates in Crohn's disease remain high. Kono-S is a novel anastomosis for ileocolonic resections; however, its altered configuration may challenge standard endoscopic assessment, particularly in the absence of validated scoring tools. This study evaluated the endoscopic assessment of Kono-S anastomosis anatomy and recurrence stratification using Rutgeert's score.
View Article and Find Full Text PDFEPIDEMIOLOGICAL AND CLINICAL PROFILE OF CROHN'S DISEASE IN A BRAZILIAN REFERRAL CENTER IN 30 YEARS OF FOLLOW-UP.
Arq Gastroenterol
September 2025
Universidade Federal de Minas Gerais, Faculdade de Medicina, Departamento de Clínica Médica, Belo Horizonte, MG, Brasil.
Background: Crohn's disease (CD) is a chronic inflammatory disease, with a heterogeneous clinical course, which can affect any segment of the gastrointestinal tract. Data on the natural history of CD in developing countries are rare.
Objective: to delineate the clinical, epidemiological, and longitudinal characteristics of CD patients at a Brazilian referral center.